vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $196.0M, roughly 1.4× Axsome Therapeutics, Inc.). KILROY REALTY CORP runs the higher net margin — 6.3% vs -14.6%, a 20.9% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -5.0%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -1.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
AXSM vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $272.2M |
| Net Profit | $-28.6M | $17.1M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 6.3% |
| Revenue YoY | 65.0% | -5.0% |
| Net Profit YoY | 61.9% | -73.7% |
| EPS (diluted) | $-0.55 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $272.2M | ||
| Q3 25 | $171.0M | $279.7M | ||
| Q2 25 | $150.0M | $289.9M | ||
| Q1 25 | $121.5M | $270.8M | ||
| Q4 24 | $118.8M | $286.4M | ||
| Q3 24 | $104.8M | $289.9M | ||
| Q2 24 | $87.2M | $280.7M | ||
| Q1 24 | $75.0M | $278.6M |
| Q4 25 | $-28.6M | $17.1M | ||
| Q3 25 | $-47.2M | $162.3M | ||
| Q2 25 | $-48.0M | $79.6M | ||
| Q1 25 | $-59.4M | $43.7M | ||
| Q4 24 | $-74.9M | $65.0M | ||
| Q3 24 | $-64.6M | $57.7M | ||
| Q2 24 | $-79.3M | $54.5M | ||
| Q1 24 | $-68.4M | $55.7M |
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — | ||
| Q1 24 | -89.7% | — |
| Q4 25 | -14.6% | 6.3% | ||
| Q3 25 | -27.6% | 58.0% | ||
| Q2 25 | -32.0% | 27.4% | ||
| Q1 25 | -48.9% | 16.1% | ||
| Q4 24 | -63.1% | 22.7% | ||
| Q3 24 | -61.7% | 19.9% | ||
| Q2 24 | -91.0% | 19.4% | ||
| Q1 24 | -91.1% | 20.0% |
| Q4 25 | $-0.55 | $0.11 | ||
| Q3 25 | $-0.94 | $1.31 | ||
| Q2 25 | $-0.97 | $0.57 | ||
| Q1 25 | $-1.22 | $0.33 | ||
| Q4 24 | $-1.54 | $0.50 | ||
| Q3 24 | $-1.34 | $0.44 | ||
| Q2 24 | $-1.67 | $0.41 | ||
| Q1 24 | $-1.44 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $5.4B |
| Total Assets | $689.8M | $10.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $179.3M | ||
| Q3 25 | $325.3M | $372.4M | ||
| Q2 25 | $303.0M | $193.1M | ||
| Q1 25 | $300.9M | $146.7M | ||
| Q4 24 | $315.4M | $165.7M | ||
| Q3 24 | $327.3M | $625.4M | ||
| Q2 24 | $315.7M | $835.9M | ||
| Q1 24 | $331.4M | $855.0M |
| Q4 25 | $88.3M | $5.4B | ||
| Q3 25 | $73.7M | $5.5B | ||
| Q2 25 | $73.1M | $5.4B | ||
| Q1 25 | $53.2M | $5.4B | ||
| Q4 24 | $57.0M | $5.4B | ||
| Q3 24 | $92.9M | $5.4B | ||
| Q2 24 | $102.9M | $5.4B | ||
| Q1 24 | $144.0M | $5.4B |
| Q4 25 | $689.8M | $10.9B | ||
| Q3 25 | $669.3M | $11.0B | ||
| Q2 25 | $639.8M | $10.9B | ||
| Q1 25 | $596.7M | $10.9B | ||
| Q4 24 | $568.5M | $10.9B | ||
| Q3 24 | $561.5M | $11.4B | ||
| Q2 24 | $548.2M | $11.5B | ||
| Q1 24 | $545.7M | $11.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $566.3M |
| Free Cash FlowOCF − Capex | $-18.7M | $450.3M |
| FCF MarginFCF / Revenue | -9.6% | 165.4% |
| Capex IntensityCapex / Revenue | 0.0% | 42.6% |
| Cash ConversionOCF / Net Profit | — | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $566.3M | ||
| Q3 25 | $1.0M | $176.6M | ||
| Q2 25 | $-32.4M | $143.7M | ||
| Q1 25 | $-43.4M | $136.9M | ||
| Q4 24 | $-26.2M | $541.1M | ||
| Q3 24 | $-18.6M | $176.3M | ||
| Q2 24 | $-30.1M | $88.7M | ||
| Q1 24 | $-53.5M | $167.9M |
| Q4 25 | $-18.7M | $450.3M | ||
| Q3 25 | $988.0K | $148.7M | ||
| Q2 25 | $-32.4M | $118.4M | ||
| Q1 25 | $-43.7M | $115.6M | ||
| Q4 24 | $-26.2M | $440.8M | ||
| Q3 24 | $-18.7M | $147.2M | ||
| Q2 24 | $-30.2M | $69.5M | ||
| Q1 24 | $-53.6M | $151.9M |
| Q4 25 | -9.6% | 165.4% | ||
| Q3 25 | 0.6% | 53.1% | ||
| Q2 25 | -21.6% | 40.9% | ||
| Q1 25 | -36.0% | 42.7% | ||
| Q4 24 | -22.1% | 153.9% | ||
| Q3 24 | -17.9% | 50.8% | ||
| Q2 24 | -34.6% | 24.7% | ||
| Q1 24 | -71.4% | 54.5% |
| Q4 25 | 0.0% | 42.6% | ||
| Q3 25 | 0.0% | 10.0% | ||
| Q2 25 | 0.0% | 8.7% | ||
| Q1 25 | 0.3% | 7.9% | ||
| Q4 24 | 0.0% | 35.0% | ||
| Q3 24 | 0.1% | 10.1% | ||
| Q2 24 | 0.1% | 6.8% | ||
| Q1 24 | 0.1% | 5.7% |
| Q4 25 | — | 33.10× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 8.32× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | — | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
